Amendment: SEC Form SC 13G/A filed by Savara Inc.

11/12/24 10:25:33 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SVRA alert in real time by email

SC 13G/A 1 SVRA09302024.txt SVRA09302024 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name of Issuer: Savara Inc. Title of Class of Securities: Common Stock CUSIP Number: 805111101 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 805111101 1. Name of Reporting Person: Jennison Associates LLC S.S. or I.R.S. Identification No. of Above Person: IRS Identification #52-2069785 (formerly 13-2631108) 2. Check the Appropriate Box if a Member of a Group: Not Applicable 3. SEC Use Only 4. Citizenship or Place of Organization: Delaware Number of Shares Beneficially Owned By Each Reporting Person With: 5. Sole Voting Power: 6,732,776 shares 6. Shared Voting Power: 0 shares 7. Sole Dispositive Power: 0 shares 8. Shared Dispositive Power: 6,732,776 shares 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 6,732,776 shares 10. Check Box if the Aggregate Amount in Row 9 Excludes Certain Shares: ( ) 11. Percent of Class Represented by Amount in Row 9: 4.1% 12. Type of Reporting Person*: IA Item 1(a) Name of Issuer: Savara Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 1717 Langhorne Newtown Road, Suite 300 Langhorne, PA 19047 Item 2(a) Name of Person Filing: Jennison Associates LLC Item 2(b) Address of Principal Business Office or Residence: 466 Lexington Avenue New York, NY 10017 Item 2(c) Citizenship: Delaware Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 805111101 Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), or (c) check whether the person filing is a: (a) ( ) Broker or Dealer registered under Section 15 of the Act (b) ( ) Bank as defined in Section 3(a) (6) of the Act (c) ( ) Insurance Company as defined in Section 3(a) (19) of the Act (d) ( ) Investment Company registered under Section 8 of the Investment Company Act (e) (X) Investment Adviser in accordance with Section 240.13d-1(b) (1) (ii) (E) (f) ( ) Employee Benefit Plan, Pension Fund which is subject to the provision of the Employee Retirement Income Security Act of 1974 or Endowment Fund in accordance with Section 240.13d-1(b) (ii) (F) (g) ( ) Parent Holding Company or control person, in accordance with Section 240.13(b) (ii) (G) (h) ( ) A savings association as defined by Section 3(b) of the Federal Deposit Insurance Act (i)( ) A church plan that is excluded from the definition of an investment company under Section 3(c) (4) of the Investment Company Act of 1940. (j)( ) Group, in accordance with Section 240.13d-1(b) (1) (ii) (J). If this statement is filed pursuant to Section 240.13d-1(c), check this box. ( ) Item 4 Ownership: Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 6,732,776 shares (b) Percent of Class: 4.1% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: 6,732,776 shares (ii) shared power to vote or to direct the vote: 0 shares (iii) sole power to dispose or to direct the disposition of: 0 shares (iv) shared power to dispose or to direct the disposition of: 6,732,776 shares Jennison Associates LLC ("Jennison") furnishes investment advice to several investment companies, insurance separate accounts, and institutional clients ("Managed Portfolios"). As a result of its role as investment adviser of the Managed Portfolios, Jennison may be deemed to be the beneficial owner of the shares of the Issuer's Common Stock held by such Managed Portfolios. Prudential Financial, Inc. ("Prudential") indirectly owns 100% of equity interests of Jennison. As a result, Prudential may be deemed to have the power to exercise or to direct the exercise of such voting and/or dispositive power that Jennison may have with respect to the Issuer's Common Stock held by the Managed Portfolios. Jennison does not file jointly with Prudential, as such, shares of the Issuer's Common Stock reported on Jennison's 13G may be included in the shares reported on the 13G filed by Prudential. These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Jennison is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares. Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the securities, check the following ( X ). Item 6 Ownership of More than Five Percent on Behalf of Another Person: Our clients have the right to receive or the power to direct the receipt of dividends or the profits from the sale of such securities. No one client owns more than 5% of such security class. Item 7 Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company: Not Applicable Item 8 Identification and Classification of Members of the Group: Not Applicable Item 9 Notice of Dissolution of Group: Not Applicable Item 10 Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are in held the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the correct information set forth in this statement is true, complete and correct. November 12, 2024 /s/ Beata Markowicz Beata Markowicz Vice President

Get the next $SVRA alert in real time by email

Recent Analyst Ratings for

$SVRA

Date	Price Target	Rating	Analyst
10/20/2025	$7.00	Overweight	Wells Fargo
8/15/2025	$5.00	Neutral → Buy	H.C. Wainwright
5/29/2025	$2.00	Buy → Neutral	H.C. Wainwright
12/20/2024	$8.00	Overweight	Wells Fargo
11/13/2024	$7.00 → $5.00	Outperform → In-line	Evercore ISI
2/15/2024	$8.00	Mkt Outperform	JMP Securities
11/7/2023	$7.00	Buy	Guggenheim
5/16/2023	$2.00 → $4.00	Hold → Buy	Jefferies

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Savara Inc.

11/12/24 10:25:33 AM ET

$SVRA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SVRA alert in real time by email

Recent Analyst Ratings for

$SVRA

Date	Price Target	Rating	Analyst
10/20/2025	$7.00	Overweight	Wells Fargo
8/15/2025	$5.00	Neutral → Buy	H.C. Wainwright
5/29/2025	$2.00	Buy → Neutral	H.C. Wainwright
12/20/2024	$8.00	Overweight	Wells Fargo
11/13/2024	$7.00 → $5.00	Outperform → In-line	Evercore ISI
2/15/2024	$8.00	Mkt Outperform	JMP Securities
11/7/2023	$7.00	Buy	Guggenheim
5/16/2023	$2.00 → $4.00	Hold → Buy	Jefferies

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Savara Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$SVRA

Amendment: SEC Form SC 13G/A filed by Savara Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$SVRA

$SVRA
SEC Filings

Savara Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 144 filed by Savara Inc.

Amendment: SEC Form SCHEDULE 13D/A filed by Savara Inc.

$SVRA
Analyst Ratings

Wells Fargo initiated coverage on Savara with a new price target

Savara upgraded by H.C. Wainwright with a new price target

Savara downgraded by H.C. Wainwright with a new price target

$SVRA
Insider Trading

Director Ramsay David A sold $121,220 worth of shares (20,000 units at $6.06), decreasing direct ownership by 0.78% to 2,533,642 units (SEC Form 4)

Chief Financial Officer Lowrance David L covered exercise/tax liability with 62,960 shares and gifted 32,000 shares, decreasing direct ownership by 25% to 286,045 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Pauls Matthew covered exercise/tax liability with 195,705 shares and gifted 128,995 shares, decreasing direct ownership by 21% to 1,188,050 units (SEC Form 4)

$SVRA
Press Releases

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

$SVRA
Insider Purchases

Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

$SVRA
Financials

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

$SVRA
Leadership Updates

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

Savara Announces Resignation of Chief Medical Officer

$SVRA
Large Ownership Changes

SEC Form SC 13G filed by Savara Inc.